Joey Ton, Michael R. Kolber
Abstract
To prevent gout recurrence, should we prescribe urate-lowering therapies (eg, allopurinol) to target uric acid levels? Best evidence finds that increasing the dosage of allopurinol to achieve a serum urate target (eg, < 360 μmol/L) does not reduce gout flares, pain, or function compared with
OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
To prevent gout recurrence, should we prescribe urate-lowering therapies (eg, allopurinol) to target uric acid levels? Best evidence finds that increasing the dosage of allopurinol to achieve a serum urate target (eg, < 360 μmol/L) does not reduce gout flares, pain, or function compared with
Key concepts: Allopurinol, Gout, Uric acid, Medicine, Febuxostat, Hyperuricemia, Internal medicine, Pharmacology